Commercial models

Pay-per-procedure came for orthopaedics.

MSKvalue Insights · July 2026 · For surgery-center and MSK service-line leaders

For twenty years, orthopaedic MedTech sold the way mainframe computing sold: put a large object in the building, then monetize everything that touches it. The robot is the visible version — seven-figure capital*, a service contract, and an implant catalog that only fits that platform. The quiet version is the same deal without the robot: instrument sets, loaner logistics, and a rep relationship, all priced into an implant invoice the facility pays whether the episode goes well or badly.

That model made sense for the seller. It never made sense for the buyer, because the buyer was never actually purchasing a device. The buyer was purchasing a procedure — one patient, one plan, one outcome — and paying for it as if buying infrastructure.

The device isn’t the product. The procedure is.

Cardiology worked this out first: the economics of a cath lab are organized around per-procedure consumption, and the commercial conversation follows the case, not the console. Orthopaedics arrived at the same place by a different road — the bundle. Once BPCI and CJR (and now the mandatory TEAM model, with CJR-X finalized July 31, 2026 for a nationwide January 2028 start) made the facility accountable for the whole episode, the unit of account stopped being “the implant” and became “the case.” Anything priced per-building instead of per-case is now a mismatch between how you pay and how you’re paid.

A capital purchase is a bet that your future volume, at unknown margins, will amortize a machine at yesterday’s prices. A per-case fee is not a bet at all: cost attaches to clinical activity, scales down when volume does, and shows up on the same line as the revenue it produced.

What pay-per-case changes for a center

The buy-side of the shift

Every MedTech commercial team is now rebuilding its model around procedures instead of platforms. MSKvalue writes for the buy side of that shift: the center deciding whether a per-case service pays for itself inside a mandatory episode. The questions to ask are worked through in the per-case economics post.

The mainframe era of orthopaedics is ending the way the mainframe era usually ends: not because the machines stopped working, but because the buyers stopped needing to own them.

Start the conversation →

Figures marked * are illustrative and program-dependent; not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.